EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Crinetics Pharmaceuticals, Inc. (CRNX) had EBITDA of $-133.41M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$25.12M
Net Income	$-120.86M
Cost of Goods Sold	$0.15M
Gross Profit	$24.96M
Operating Expenses	$157.58M
Operating Income	$-132.46M
Non-Operating Income/Expense	$11.60M
Pre-Tax Income	$-120.86M
Normalized Pre-Tax Income	$-120.86M
Income after Taxes	$-120.86M
Income from Continuous Operations	$-120.86M
Consolidated Net Income/Loss	$-120.86M
Normalized Income after Taxes	$-120.86M
EBIT	$-132.46M
EBITDA	$-133.41M
Weighted-Average Shares Outstanding (Basic)	105.56M
Weighted-Average Shares Outstanding (Diluted)	105.56M
Earnings per Share (EPS) (Basic)	$-1.14
Earnings per Share (EPS) (Diluted)	$-1.14
Balance Sheet Financials
Current Assets	$1.24B
Property, Plant, and Equipment	$13.07M
Long-Term Assets	$77.52M
Total Assets	$1.32B
Current Liabilities	$79.92M
Long-Term Debt	--
Long-Term Liabilities	$50.01M
Total Liabilities	$129.92M
Common Equity	$1.19B
Tangible Shareholders Equity	$1.19B
Shareholders Equity	$1.19B
Common Shares Outstanding	105.81M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-218.90M
Cash Flow from Investing Activities	$-226.07M
Cash Flow from Financial Activities	$398.80M
Beginning Cash	$102.34M
End Cash	$56.30M
Increase/Decrease in Cash	$-46.04M
Stock-Based Compensation	$54.56M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	15.57
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	99.39%
Operating Margin	-527.35%
EBIT Margin	-527.35%
EBITDA Margin	--
Pre-Tax Profit Margin	-481.15%
Profit Margin	-481.15%
Free Cash Flow	$-220.24M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.02
Inventory Turnover	0.04
Receiveable Turnover	2.10
Days Sales in Receivables	42.84
Return on Equity	-10.14%
Return on Tangible Equity	-10.14%
Return on Assets	-9.14%
Return on Investments	-10.14%
Book Value Per Share	$11.27
Free Cash Flow per Share	$-2.09
Operating Cash Flow per Share	$-2.07

Data from Zacks Investment Research, Inc.